

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (Cancelled)

9. (Previously Presented) A method according to claim 11, wherein the estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate, N-acylsulfamate of estrone, estradiol or estriol having an acyl chain of up to 7 C atoms or mixtures thereof.

10. (Cancelled)

11. (Previously Presented) A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 0.5-5.0 mg on each day when administered in intervals of 5-10 days.

12. (Cancelled)

13. (Previously Presented) A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 2.0-20 mg on each day when administered in intervals of 20-40 days.

14. (Previously Presented) A method according to claim 11, further comprising the administration of a gestagen.

15. (Previously Presented) A method according to claim 14, wherein the at least one gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a mixture thereof.

16. (Previously Presented) A method according to claim 14, wherein the at least one gestagen is continuously administered.

17. (Previously Presented) A method according to claim 16, wherein the continuous administration is in the form of an implant, in the form of an intrauterine release system or in the form of a combination thereof.

18. (New) A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 20-300 µg/day in intervals of 2 or 3 days; 0.5-5.0 mg/day in intervals of 5-10 days; or 2.0-20 mg/day in intervals of 20-40 days.

19. (New) A method according to claim 18, wherein the estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate, N-acylsulfamate of estrone, estradiol or estriol having an acyl chain of up to 7 C atoms or mixtures thereof.

20. (New) A method according to claim 18, wherein the intermittent oral administration is carried out at an interval of 2 to 40 days between administrations.

21. (New) A method according to claim 18, wherein the intermittent oral administration is carried out at an interval of 2 to 3 days between administrations.

22. (New) A method according to claim 18, further comprising the administration of a gestagen.

23. (New) A method according to claim 22, wherein the at least one gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a mixture thereof.

24. (New) A method according to claim 22, wherein the at least one gestagen is continuously administered.

25. (New) A method according to claim 24, wherein the continuous administration is in the form of an implant, in the form of an intrauterine release system or in the form of a combination thereof.